Dr.Max, the pharmacy retail operator backed by Penta Investments Limited, has completed its acquisition of 18 pharmacies from Marcos Provit, which operates under the Evofarm brand in Romania. The Competition Council has granted approval for the transaction, determining that the deal does not create competitive concerns in the Romanian market.
Regulatory Approval Signals Market Confidence
Romania’s Competition Council conducted a thorough assessment of the acquisition before clearing it for completion. The regulatory body found that the transaction poses no significant threat to fair competition in the country. In its official determination, the authority stated: “After analysis, the Competition Council found that this operation does not raise significant obstacles to effective competition in the Romanian market or a substantial part of it, and there are no serious doubts about its compatibility with a normal competitive environment.”
The approval underscores the regulators’ confidence that Dr.Max’s expansion through this acquisition will not concentrate market power in ways that disadvantage consumers or competitors. The 18 pharmacies being acquired are spread across several Romanian counties, bringing geographically dispersed assets into Dr.Max’s growing network.
Strategic Expansion in Healthtech Retail
The transaction represents a meaningful expansion of Dr.Max’s footprint in one of Eastern Europe’s significant pharmacy markets. By integrating the Evofarm locations, Dr.Max strengthens its position as a major player in Romanian pharmacy retail, a sector that continues to attract investment and consolidation across the region.
The acquisition follows a broader pattern of healthtech and pharmacy retail companies seeking to build scale through strategic M&A activity. For Dr.Max, the addition of these locations provides immediate market presence and an established customer base across multiple regions, potentially creating operational efficiencies and improved service coverage.
European Market Consolidation Trends
This acquisition reflects ongoing consolidation within European pharmacy retail, where companies seek to build national and regional networks capable of competing effectively against both traditional independent pharmacies and large multinational chains. Romania’s pharmacy market has seen increased activity from ambitious retailers looking to modernize service delivery and expand their reach.
The deal, backed by Penta Investments Limited, demonstrates continued capital availability for European healthtech and pharmacy businesses, even as market conditions remain selective. Investors remain focused on businesses demonstrating clear pathways to profitability and market leadership in their regions.
As European pharmacy retail continues to evolve with digital health services, omnichannel offerings, and regulatory changes, acquisitions like Dr.Max’s Evofarm purchase highlight how traditional retail pharmacies remain valuable assets when positioned within larger networks capable of delivering integrated healthcare solutions.